Liz Highleyman

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

The pre-inauguration event on January 19 will be a national moment of unity and remembrance.

Long-lived memory immune cells continue to provide protection even after antibody levels drop.

With the vaccine rollout going slowly, experts debate delayed second dose and other strategies.

The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.

New guidelines recommend focusing on healthy foods but don’t restrict added sugars or alcohol as much as some experts had hoped.

The gym may be closed, but you can still exercise at home or outdoors.

Ask POZ is an ongoing section on POZ.com dedicated to answering general wellness questions.

Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.

A refined mapping of HIV’s reservoir could aid in cure research.

Resistance to four HIV drug classes is tied to high risk of disease and death.

Larger studies suggest people living with HIV might have a modestly higher risk of severe COVID-19, but much remains to be learned.

COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.

Anthony Fauci, President-elect Joe Biden and senior legislators were vaccinated publicly to demonstrate their confidence in vaccine safety.

The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.